v3.26.1
Acquisitions, divestitures and other arrangements - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended 24 Months Ended
Dec. 26, 2025
Apr. 02, 2025
Dec. 28, 2025
Jan. 02, 2028
Mar. 29, 2026
Business Combination [Line Items]          
Payments to acquire businesses     $ 17,500    
Goodwill (Note 3)     $ 48,772   $ 48,558
Royalty Pharma plc.          
Business Combination [Line Items]          
Milestone payments receivable         $ 500
Scenario, Forecast          
Business Combination [Line Items]          
Other commitment, maximum funds to receive       $ 500  
Halda Therapeutics          
Business Combination [Line Items]          
Payments to acquire businesses $ 3,050        
Acquisition related costs 200        
Assets acquired including goodwill 3,400        
Goodwill (Note 3) 600        
Liabilities assumed 600        
Halda Therapeutics | In-process research and development          
Business Combination [Line Items]          
Asset acquired, identifiable intangible asset, indefinite-lived $ 2,800        
Intra-Cellular Therapies, Inc.          
Business Combination [Line Items]          
Acquisition related costs   $ 400      
Goodwill (Note 3)   2,900      
Liabilities assumed   $ 3,000      
Share price (in dollars per share)   $ 132.00      
Consideration transferred   $ 14,500      
Integration-related cost, expense   100      
Assets acquired   17,500      
Amortizable intangibles asset   5,200      
Business combination, other asset   1,100      
Intra-Cellular Therapies, Inc. | In-process research and development          
Business Combination [Line Items]          
Asset acquired, identifiable intangible asset, indefinite-lived   $ 8,300